

Ethnicity is not biology: retinal pigment score to evaluate biological variability from ophthalmic imaging using machine learning

Table of contents

Supplementary material	3
Supplementary methods	3
GWAS analysis	3
Mendelian randomisation	4
Supplementary results	5
Supplementary Table 1. Baseline cohort characteristics by tertiles of retinal pigment score (RPS).	5
Supplementary Table 2: Multivariable Linear regression results.	6
Supplementary Table 3: Prioritised gene set from the discovery UK Biobank genome-wide association study.	7
Supplementary Table 4: EPIC-Norfolk GWAS results	11
Supplementary Table 5: PheWAS table of results	13
Supplementary Table 6. Details of summary-level data used for Mendelian randomization analyses.	16
Supplemental Table 7. Mendelian randomization results for potentially causal associations between retinal pigment score with selected outcomes of interest.	17
Supplementary Table 8. Tests of heterogeneity, directional pleiotropy and regression dilution statistics for the retinal pigment score instrumental variable	18
Supplementary Figure 1: Adjusted Regression plots. Adjusted mean retinal pigment score by covariates of interest. Adjusted means (solid black dots), 95% confidence intervals (vertical solid lines), and regression line for continuous variables (dotted line) are from a linear regression model adjusting for age, sex, and UK biobank centre. *M, myopia; E, emmetropia; H, hyperopia.	19
Supplementary Figure 2. Traits that are significantly enriched for prioritised genes from the discovery genome-wide association study, as evidenced by previously reported gene-trait associations in the GWAS Catalog.	20
Supplementary Figure 3. Gene Ontology biological pathways from MsigDB significantly enriched for prioritised genes from the discovery genome-wide association study.	20
Supplementary Figure 4: PheWAS Volcano Plot	21

Supplementary material

Supplementary methods

Details of the overall UK Biobank study protocol and protocols for individual tests are available online (<https://biobank.ndph.ox.ac.uk/ukb/index.cgi>).

The choices for ethnic background in UK Biobank were categorised as white, Mixed, Asian or Asian British, black or black British, Chinese, or other ethnic group.
(<https://biobank.ndph.ox.ac.uk/ukb/index.cgi>).

The European Prospective Investigation into Cancer and Nutrition-Norfolk (EPIC-Norfolk) Eye Study protocol is available online at <https://www.epic-norfolk.org.uk/>.

GWAS analysis

Full details for genotyping and imputation in the UK Biobank cohort have been described previously.[1] In brief, genotype calling was performed using two arrays: the UK BiLEVE Axiom array (~50,000 participants) and the UK Biobank Axiom array (~450,000 participants). Marker positions are in GRCh37 coordinates. There were 805,426 markers available in the released data after quality control. Genotype imputation was then performed using a combined Haplotype Reference Consortium and UK10K reference panel, expanding the number of testable variants to ~96 million. The majority of the EPIC-Norfolk cohort were also genotyped using the Affymetrix UK Biobank Axiom Array, however, genotyping for a small subset was undertaken using the Affymetrix GeneChip Human Mapping 500K Array Set.

The following exclusions were applied for sample quality control: individuals with relatedness corresponding to third-degree relatives or closer, excess of missing genotypes or more heterozygosity than expected. The GWAS analysis was furthermore restricted to individuals of European ethnicity only. The following exclusions were applied for variant-level quality control: call rate <95%, Hardy-Weinberg equilibrium $p < 1 \times 10^{-6}$, posterior call probability <0.9, INFO score <0.9 and minor allele frequency <0.01.

The SNP2GENE function within FUMA[2] was used to perform positional and expression quantitative trait locus (eQTL) gene mapping/prioritisation. SNPs in high LD ($r^2 > 0.6$) with any independent lead variant were positionally mapped to genes located within 10kb. Variants were also mapped to a set of prioritised genes within 1Mb if associated with the expression of those genes in retina (reported in EyeGEx), skin (reported in TwinsUK, GTEx v8) and dermal fibroblasts (reported in GTEx v8). To test the prioritised genes for enrichment in biological pathways, FUMA's GENE2FUNC function was applied, using hypergeometric mean pathway analysis against gene sets obtained from MsigDB and WikiPathways. Multiple testing correction (Benjamini-Hochberg method) per data source of tested gene sets was performed and gene sets with adjusted $P \leq 0.05$ and >1 overlapping genes were reported by default.

The GWAS analysis was performed using REGENIE software.[3] GCTA-COJO was used to prioritise lead variants.[4] Genomic inflation factor and heritability estimates were calculated using the LDSC tool[5] and pre-calculated LD scores for European ancestry

(https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2). All other statistical analyses and were performed in R (R for GNU macOS, Version 4.2.0, The R Foundation for Statistical Computing, Vienna, Austria).[6] R packages used included PheWAS[7], TwoSampleMR[8], MendelianRandomization[9], ukbwranglr[10], codemapper[11], targets[12], tarchetypes[13], tidyverse [14], workflowr[15], flextable[16], gtsummary[17] and knitr.[18]

Mendelian randomisation

Two-sample Mendelian randomisation (MR) analyses were conducted drawing on the discovery RPS GWAS results (exposure) and summary statistics from the independent FinnGen cohort[19] (data release 8) for selected outcomes of interest, as highlighted by the RPS PheWAS analysis. The IV for retinal pigmentation was constructed by selecting all conditionally independent genome-wide significant single nucleotide polymorphisms (SNPs) from the discovery RPS GWAS analysis, and performing clumping to exclude those with linkage disequilibrium $R^2 > 0.01$ and within 10 000 kb, using the 1000 Genomes Project European reference population.[20] Palindromic SNPs with minor allele frequency > 0.46 were excluded. Effect alleles were harmonized across exposure and outcome datasets.

The multiplicative random-effects inverse-variance weighted (IVW) approach method used for MR analyses provides precise and efficient estimates, but is sensitive to invalid instrumental variables (IVs) and pleiotropy.[30] We therefore conducted sensitivity analyses using three alternative MR methods: weighted median[31], weighted mode[32] and MR-Egger[33]. Each method makes different assumptions about the nature of pleiotropy and consistent estimates across methods strengthens causal inferences.[34]

Under the IVW method, we calculated the mean F-statistic as an indicator of instrument strength (a value > 10 is usually considered a strong instrument).[21] We assessed for heterogeneity with the I^2 and Cochran's Q statistics in the IVW model and with Rucker's Q' statistic in MR-Egger regression. The I^2_{GX} statistic is an indicator of expected relative bias (or dilution) of the MR-Egger causal estimate.[22] In MR-Egger regression, a significant difference of the intercept from zero is evidence for average directional horizontal pleiotropy.[23]

Supplementary results

Supplementary Table 1. Baseline cohort characteristics by tertiles of retinal pigment score (RPS).

Characteristic	Overall, N = 44,320	RPS tertiles		
		1, N = 14,774	2, N = 14,773	3, N = 14,773
Retinal pigment score	-0.82 (-9.89, 10.39)	-12.64 (-15.68, -9.89)	-0.82 (-4.12, 2.59)	15.18 (10.39, 21.43)
Age	56 (49, 63)	56 (49, 62)	58 (50, 63)	55 (48, 62)
Sex				
Female	24,414 (55%)	8,109 (55%)	8,182 (55%)	8,123 (55%)
Male	19,906 (45%)	6,665 (45%)	6,591 (45%)	6,650 (45%)
Ethnicity*				
White	40,704 (92%)	14,679 (100%)	14,551 (99%)	11,474 (78%)
Black	1,135 (2.6%)	1 (<0.1%)	9 (<0.1%)	1,125 (7.7%)
Asian	1,078 (2.4%)	5 (<0.1%)	37 (0.3%)	1,036 (7.1%)
Mixed	369 (0.8%)	11 (<0.1%)	42 (0.3%)	316 (2.2%)
Chinese	161 (0.4%)	0 (0%)	2 (<0.1%)	159 (1.1%)
Other	599 (1.4%)	20 (0.1%)	64 (0.4%)	515 (3.5%)
Skin color*				
Very fair	3,583 (8.2%)	1,682 (11%)	1,226 (8.4%)	675 (4.7%)
Fair	28,889 (66%)	11,044 (75%)	10,356 (71%)	7,489 (52%)
Light olive	8,219 (19%)	1,772 (12%)	2,759 (19%)	3,688 (26%)
Dark olive	779 (1.8%)	114 (0.8%)	202 (1.4%)	463 (3.2%)
Brown	1,705 (3.9%)	23 (0.2%)	69 (0.5%)	1,613 (11%)
Black	482 (1.1%)	0 (0%)	1 (<0.1%)	481 (3.3%)
Hair color*				
Blonde	4,567 (10%)	2,317 (16%)	1,513 (10%)	737 (5.0%)
Red	1,781 (4.0%)	701 (4.8%)	644 (4.4%)	436 (3.0%)
Light brown	16,657 (38%)	6,564 (45%)	6,103 (41%)	3,990 (27%)
Dark brown	16,656 (38%)	4,572 (31%)	5,641 (38%)	6,443 (44%)
Black	3,980 (9.0%)	393 (2.7%)	648 (4.4%)	2,939 (20%)
Other	486 (1.1%)	182 (1.2%)	174 (1.2%)	130 (0.9%)
Height (in cm)	168 (162, 176)	169 (163, 176)	168 (162, 176)	168 (162, 175)
Townsend index of deprivation (quintiles)*				
1 (least deprived)	13,047 (29%)	4,723 (32%)	4,564 (31%)	3,760 (25%)
2	9,029 (20%)	3,138 (21%)	3,062 (21%)	2,829 (19%)
3	8,447 (19%)	2,796 (19%)	2,844 (19%)	2,807 (19%)
4	8,303 (19%)	2,665 (18%)	2,693 (18%)	2,945 (20%)
5 (more deprived)	5,429 (12%)	1,427 (9.7%)	1,591 (11%)	2,411 (16%)

Median (IQR) for continuous variables.

Count (column %) for categorical variables.

*Variables with missing data: ethnicity (n=274, 0.6%), skin color (n=663, 1.5%), hair color (n=193, 0.4%), Townsend index of deprivation (n=65, 0.1%)

Supplementary Table 2: Multivariable Linear regression results.

Characteristic	Beta	95% CI	p-value
Age (per 5 years)	0.20	0.13, 0.27	1.3e-08
Sex			
Female	—	—	
Male	0.17	-0.14, 0.48	0.279
Ethnicity			
White	—	—	
Black	15	14, 16	1.6e-158
Asian	14	14, 15	4.0e-216
Mixed	12	11, 13	4.7e-86
Chinese	20	18, 21	4.6e-103
Other	13	12, 14	2.8e-135
Missing	5.8	4.3, 7.4	1.4e-13
Skin color			
Very fair	—	—	
Fair	2.2	1.8, 2.6	5.9e-27
Light olive	6.3	5.8, 6.7	8.2e-147
Dark olive	7.3	6.4, 8.2	4.3e-55
Brown	9.5	8.5, 10	4.3e-88
Black	11	9.4, 12	5.7e-48
Missing	6.2	5.1, 7.2	5.2e-32
Hair color			
Blonde	—	—	
Red	3.5	2.9, 4.1	4.1e-28
Light brown	2.1	1.7, 2.5	5.1e-29
Dark brown	4.9	4.5, 5.3	1.2e-136
Black	7.0	6.4, 7.6	4.8e-122
Other	2.3	1.2, 3.3	1.9e-05
Missing	3.6	1.7, 5.5	2.0e-04
Refractive status			
Myopia <-6.00D	—	—	
Myopia	1.6	1.1, 2.2	1.3e-08
Emmetropia	2.1	1.5, 2.6	1.1e-12
Hyperopia	1.4	0.84, 2.0	1.1e-06
Hyperopia >+6.00D	-1.3	-2.9, 0.38	0.133
Height (per 5cm)	-0.24	-0.32, -0.15	3.6e-08
Townsend index of deprivation (quintiles)			
1 (least deprived)	—	—	
2	0.11	-0.19, 0.41	0.480
3	0.15	-0.16, 0.46	0.353
4	0.22	-0.10, 0.54	0.169
5 (more deprived)	0.81	0.43, 1.2	2.5e-05
Missing	-0.30	-3.0, 2.5	0.833

Differences in retinal pigment score (RPS) per specified differences in covariates. Estimates are mutually adjusted for all covariates shown in the table. Bold p-values mean statistically significant results.

Supplementary Table 3: Prioritised gene set from the discovery UK Biobank genome-wide association study.

Ensembl ID	Gene symbol
ENSG00000198625	<i>MDM4</i>
ENSG00000184144	<i>CNTN2</i>
ENSG00000174529	<i>TMEM81</i>
ENSG00000117222	<i>RBBP5</i>
ENSG00000133059	<i>DSTYK</i>
ENSG00000133069	<i>TMCC2</i>
ENSG00000163545	<i>NUAK2</i>
ENSG00000162873	<i>KLHDC8A</i>
ENSG00000066027	<i>PPP2R5A</i>
ENSG00000065600	<i>TMEM206</i>
ENSG00000117691	<i>NENF</i>
ENSG00000143801	<i>PSEN2</i>
ENSG00000163050	<i>ADCK3</i>
ENSG00000172771	<i>EFCAB12</i>
ENSG00000129071	<i>MBD4</i>
ENSG00000163913	<i>IFT122</i>
ENSG00000163914	<i>RHO</i>
ENSG00000178804	<i>HIFOO</i>
ENSG00000004399	<i>PLXND1</i>
ENSG00000151388	<i>ADAMTS12</i>
ENSG00000182631	<i>RXFP3</i>
ENSG00000164175	<i>SLC45A2</i>
ENSG00000137265	<i>IRF4</i>
ENSG00000112685	<i>EXOC2</i>
ENSG00000188996	<i>HUSIB</i>
ENSG0000028839	<i>TBPL1</i>

ENSG00000146411	<i>SLC2A12</i>
ENSG00000196367	<i>TRRAP</i>
ENSG00000198742	<i>SMURF1</i>
ENSG00000185467	<i>KPNA7</i>
ENSG00000106245	<i>BUD31</i>
ENSG00000106246	<i>PTCD1</i>
ENSG00000248919	<i>ATP5J2-PTCD1</i>
ENSG00000198556	<i>ZNF789</i>
ENSG00000160908	<i>ZNF394</i>
ENSG00000196652	<i>ZKSCAN5</i>
ENSG00000021461	<i>CYP3A43</i>
ENSG00000106261	<i>ZKSCAN1</i>
ENSG00000166529	<i>ZSCAN21</i>
ENSG00000166526	<i>ZNF3</i>
ENSG00000168090	<i>COPS6</i>
ENSG00000166508	<i>MCM7</i>
ENSG00000221838	<i>AP4MI</i>
ENSG00000106290	<i>TAF6</i>
ENSG00000197093	<i>GAL3ST4</i>
ENSG00000213420	<i>GPC2</i>
ENSG00000066923	<i>STAG3</i>
ENSG00000160844	<i>GATS</i>
ENSG00000214300	<i>SPDYE3</i>
ENSG00000121716	<i>PILRB</i>
ENSG00000085514	<i>PILRA</i>
ENSG00000078487	<i>ZCWPW1</i>
ENSG00000146834	<i>MEPCE</i>
ENSG00000160813	<i>PPP1R35</i>
ENSG00000185955	<i>C7orf61</i>
ENSG00000166925	<i>TSC22D4</i>

ENSG00000166924	<i>NYAPI</i>
ENSG00000077080	<i>ACTL6B</i>
ENSG00000172354	<i>GNB2</i>
ENSG00000146830	<i>GIGYF1</i>
ENSG00000196411	<i>EPHB4</i>
ENSG00000146828	<i>SLC12A9</i>
ENSG00000087087	<i>SRRT</i>
ENSG00000087085	<i>ACHE</i>
ENSG00000205277	<i>MUC12</i>
ENSG00000169876	<i>MUC17</i>
ENSG00000128581	<i>RABL5</i>
ENSG00000107165	<i>TYRP1</i>
ENSG00000153714	<i>LURAPIL</i>
ENSG00000110693	<i>SOX6</i>
ENSG00000110075	<i>PPP6R3</i>
ENSG00000132749	<i>MTL5</i>
ENSG00000197345	<i>MRPL21</i>
ENSG00000162341	<i>TPCN2</i>
ENSG00000172927	<i>MYEOV</i>
ENSG00000123892	<i>RAB38</i>
ENSG00000168959	<i>GRM5</i>
ENSG00000077498	<i>TYR</i>
ENSG00000086991	<i>NOX4</i>
ENSG00000172572	<i>PDE3A</i>
ENSG00000134532	<i>SOX5</i>
ENSG00000080166	<i>DCT</i>
ENSG00000152749	<i>GPR180</i>
ENSG00000104044	<i>OCA2</i>
ENSG00000128731	<i>HERC2</i>
ENSG00000183629	<i>GOLGA8G</i>

ENSG00000188626	<i>GOLGA8M</i>
ENSG00000034053	<i>APBA2</i>
ENSG00000184009	<i>ACTG1</i>
ENSG00000186765	<i>FSCN2</i>
ENSG00000185504	<i>C17orf70</i>
ENSG00000182446	<i>NPLOC4</i>
ENSG00000185527	<i>PDE6G</i>
ENSG00000204237	<i>OXLDI</i>
ENSG00000185298	<i>CCDC137</i>
ENSG00000214087	<i>ARL16</i>
ENSG00000185359	<i>HGS</i>
ENSG00000262814	<i>MRPL12</i>
ENSG00000262660	<i>SLC25A10</i>
	<i>SLC25A10</i>
ENSG00000183048	

Supplementary Table 4: EPIC-Norfolk GWAS results

Rs identifier	chr:pos [hg19]	EA/OA (EAF)	Beta (95% CI) ^P	Nearest gene	Genome-wide significant
rs6670870	1:205155177	A/T (0.76)	-0.02 (-0.07; 0.03)	4.1E-01 <i>DSTYK</i>	
rs173273	1:212446689	G/T (0.41)	-	-	<i>PPP2R5A</i>
rs762948237	3:129178587	TCTTC/T (0.87)	-	-	<i>IFT122</i>
rs16891982	5:33951693	C/G (0.02)	0.59 (0.47; 0.71)	5.1E-22 <i>SLC45A2</i>	Yes
rs12203592	6:396321	C/T (0.79)	0.13 (0.07; 0.18)	4.2E-06 <i>IRF4</i>	
rs62425803	6:134330249	G/A (0.81)	0.04 (-0.01; 0.09)	1.4E-01 <i>TCF21</i>	
rs117756744	7:100277212	G/A (0.98)	0.16 (0.02; 0.29)	2.1E-02 <i>GNB2</i>	
rs1325117	9:12613472	G/A (0.36)	0.1 (0.05; 0.14)	5.0E-06 <i>TYRP1;LURAPIL</i>	
rs11023814	11:16007053	C/G (0.43)	0.09 (0.04; 0.13)	3.1E-05 <i>SOX6</i>	
rs150527451	11:68817897	G/A (0.89)	0.17 (0.11; 0.24)	8.1E-08 <i>TPCN2</i>	
rs1060435	11:68855595	A/G (0.59)	0.04 (0; 0.08)	3.5E-02 <i>TPCN2</i>	
rs747572	11:87885082	A/G (0.63)	0.05 (0.01; 0.1)	8.6E-03 <i>CTSC</i>	
rs1126809	11:89017961	G/A (0.7)	0.06 (0.02; 0.11)	3.7E-03 <i>TYR</i>	

rs4762973	12:20710145	A/G (0.75)	0.05 (0; 0.1)	2.8E-02	<i>PDE3A</i>	
rs10771034	12:23979199	T/A (0.45)	-0.06 (- 0.1; - 0.02)	3.3E-03	<i>SOX5</i>	
rs766338951	13:95169060	CT/C (0.69)	-	-	<i>DCT</i>	
rs1800407	15:28230318	C/T (0.91)	0.14 (0.06; 0.21)	3.4E-04	<i>OCA2</i>	
rs12913832	15:28365618	A/G (0.22)	0.53 (0.48; 0.58)	1.2E-98	<i>HERC2</i>	Yes
rs7220155	17:79606020	C/T (0.62)	-0.07 (- 0.11; - 0.02)	1.7E-03	<i>TSPAN10</i>	
rs1785433	21:44783282	A/G (0.65)	-0.05 (- 0.1; - 0.01)	9.0E-03	<i>SIK1</i>	

Supplementary Table 5: PheWAS table of results

Table of retinal pigment score phenome-wide association study results meeting the nominal significance threshold ($p < 0.05$).

category	phenotype	n_cases	n_controls	pOR (95% CI)
Benign Neoplasm/CIN				
	Benign neoplasm and polyp of uterus	1,042	36,025	0.0230 ^{1.08 (1.01; 1.15)}
Cancers				
	Primary Malignancy_Other Skin and subcutaneous tissue	2,334	34,733	0.0000 ^{0.9 (0.86; 0.94)}
	Primary Malignancy_Malignant Melanoma	644	36,423	0.0172 ^{0.91 (0.83; 0.98)}
Circulatory System				
	Myocardial infarction	1,482	35,585	0.0165 ^{1.07 (1.01; 1.13)}
	Venous thromboembolic disease (Excl PE)	1,095	35,972	0.0232 ^{1.07 (1.01; 1.14)}
Digestive System				
	Gastro-oesophageal reflux disease	5,622	31,445	0.0015 ^{0.95 (0.93; 0.98)}
	Abdominal Hernia	4,355	32,712	0.0027 ^{1.05 (1.02; 1.09)}
	Diverticular disease of intestine (acute and chronic)	4,484	32,583	0.0198 ^{1.04 (1.01; 1.07)}
Eye				
	Diabetic ophthalmic complications	629	36,438	0.0293 ^{0.91 (0.84; 0.99)}
	Anterior and Intermediate Uveitis	205	36,862	0.0324 ^{0.86 (0.74; 0.99)}

	Retinal detachments and breaks	449	36,618	0.04800.91 (0.82; 1)
Genitourinary system				
	Postcoital and contact bleeding	323	36,744	0.0315 ^{0.88 (0.79;} _{0.99)}
	Erectile dysfunction	1,201	35,866	0.03630.94 (0.88; 1)
Haematological/Immunological conditions				
	Agranulocytosis	490	36,577	0.0020 ^{0.86 (0.78;} _{0.95)}
Infectious Diseases				
	Infection of skin and subcutaneous tissues	1,462	35,605	0.0004 ^{1.1 (1.04;} _{1.16)}
	Lower Respiratory Tract Infections	3,035	34,032	0.0024 ^{1.06 (1.02;} _{1.1)}
	Bacterial Diseases (excl TB)	5,091	31,976	0.0090 ^{1.04 (1.01;} _{1.07)}
	Other or unspecified infectious organisms	4,922	32,145	0.02191.04 (1; 1.07)
Mental Health Disorders				
	Schizophrenia, schizotypal and delusional disorders	154	36,913	0.0026 ^{1.26 (1.08;} _{1.47)}
Musculoskeletal conditions				
	Fracture of hip	314	36,753	0.0062 ^{1.17 (1.04;} _{1.31)}
	Spondylolisthesis	213	36,854	0.0063 ^{1.2 (1.05;} _{1.38)}
	Carpal tunnel syndrome	1,673	35,394	0.0252 ^{1.06 (1.01;} _{1.11)}

Neurological conditions

Migraine 2,462 34,605 0.0000 $0.91(0.87; 0.95)$

Respiratory System

COPD 1,664 35,403 0.0001<sup>1.11 (1.05;
1.16)</sup>

Allergic and chronic rhinitis 4,310 32,757 0.0002<sup>0.94 (0.91;
0.97)</sup>

Chronic sinusitis 2,992 34,075 0.0073<sup>0.95 (0.91;
0.99)</sup>

Pulmonary collapse (excl pneumothorax) 450 36,617 0.04171.1 (1; 1.21)

Skin conditions

Actinic keratosis 1,058 36,009 0.0000^{0.87 (0.81; 0.93)}

Rosaceae 857 36,210 0.0019<sup>0.9 (0.83;
0.96)</sup>

Seborrheic dermatitis 967 36,100 0.03270.93 (0.87; 1)

Supplementary Table 6. Details of summary-level data used for Mendelian randomization analyses.

Trait	Source	Description	Participants (cases/controls)
Exposure			
Retinal pigment score	UK Biobank	-	37,067
Outcome			
<i>Dermatological</i>			
Actinic keratosis	FinnGen	finngen_R8_L12_ACTINKERA	(9 319 / 331 962)
Basal cell carcinoma of skin	FinnGen	finngen_R8_C3_BASAL_CELL_CARCINOMA_EXALLC	(16 328 / 259 583)
Squamous cell carcinoma of skin	FinnGen	finngen_R8_C3_SQUAMOUS_CELL_CARCINOMA_SKIN_EXALLC	(2 749 / 259 583)
Malignant melanoma of skin	FinnGen	finngen_R8_C3_MELANOMA_SKIN_EXALLC	(2 705 / 259 583)
Other non-melanoma skin cancer	FinnGen	finngen_R8_C3_OTHER_SKIN_EXALLC	(14 863 / 259 583)
<i>Other</i>			
COPD	FinnGen	finngen_R8_J10_COPD	(16 410 / 283 589)
Migraine	FinnGen	finngen_R8_G6_MIGRAINE	(15 905 / 264 662)

Abbreviations: SNP = single nucleotide polymorphism; IV = instrumental variable; COPD = chronic obstructive pulmonary disease.

Supplemental Table 7. Mendelian randomization results for potentially causal associations between retinal pigment score with selected outcomes of interest.


	Actinic keratosis	Basal cell carcinoma of skin	Squamous cell carcinoma of skin	Malignant melanoma of skin	Non-melanoma skin cancer	COPD	Migraine
MR method	O dd % s rat io	O dd % s rat io	O dd % s rat io	O dd % s rat io	O dd % s rat io	O dd % s rat io	O dd % s rat io
IVW	0. 0. 0. 0. 44 23 82 01 1 6 7 1	0. 0. 0. 0. 59 38 91 01 1 2 6 9	0. 0. 0. 0. 38 20 72 00 4 2 9 3	0. 0. 0. 0. 40 22 73 00 4 3 0 3	0. 0. 0. 0. 59 38 93 02 7 1 6 5	1. 0. 1. 0. 08 95 22 23 0 0 8 9	1. 0. 1. 0. 03 86 22 72 1 8 6 6
Weighted median	0. 0. 0. <0 61 47 79 .0 1 1 4 01	0. 0. 0. <0 65 54 77 .0 0 4 6 01	0. 0. 0. 0. 54 36 80 00 1 5 2 2	0. 0. 0. <0 44 31 62 .0 1 3 1 01	0. 0. 0. <0 66 54 80 .0 4 9 4 01	1. 0. 1. 0. 10 96 26 14 6 6 7 4	0. 0. 1. 0. 97 82 14 72 1 6 1 1
Weighted mode	0. 0. 0. 0. 63 50 79 00 1 1 4 2	0. 0. 0. 0. 68 57 83 00 9 1 1 2	0. 0. 0. 0. 48 32 72 00 3 0 8 5	0. 0. 0. <0 44 31 62 .0 1 4 0 01	0. 0. 0. 0. 71 59 85 00 3 2 9 4	1. 0. 1. 0. 12 98 29 11 5 1 2 8	0. 0. 1. 0. 94 78 14 59 9 5 7 7
MR-Egger	0. 0. 0. 0. 28 09 86 02 2 2 3 7	0. 0. 0. 0. 43 20 93 03 4 1 5 3	0. 0. 0. 0. 26 08 84 02 4 3 8 5	0. 0. 1. 0. 44 15 33 14 7 0 0 8	0. 0. 0. 0. 44 20 99 04 8 2 2 8	1. 0. 1. 0. 19 96 48 09 7 9 1 6	1. 0. 1. 0. 00 74 36 97 6 2 3 1

* Odds ratios expressed per standard deviation increase in retinal pigment score.


Supplementary Table 8. Tests of heterogeneity, directional pleiotropy and regression dilution statistics for the retinal pigment score instrumental variable

MR method	Actinic keratosis	Basal cell carcinoma of skin	Squamous cell carcinoma of skin	Malignant melanoma of skin	Other non- melanoma skin cancer	COPD	Migraine					
	Estim ate	P- value	Estim ate	P- value	Estim ate	P- value	Estim ate	P- value				
IVW												
Cochran's Q statistic	280.3 (12)	<0.00 1	217.5 (12)	<0.00 1	87.4 (12)	<0.00 1	77.7 (12)	<0.00 1				
I^2 statistic	95.7 %	-	94.5 %	-	86.3% -	84.6 %	94.3% -	40.8 %	-	68.1 %	-	
MR- Egger												
Rucker's Q' statistic	259.1 (11)	<0.00 1	200.7 (11)	<0.00 1	83.1 (11)	<0.00 1	77.3 (11)	<0.00 1				
I^2_{GX} statistic	94.9 %	-	95.3 %	-	94.8% -	95.5 %	95.3% -	96.1 %	-	96.2 %	-	
Intercept	0.046 0.343	0.343	0.032 0.336	0.336	0.038 0.449	0.449	0.011 0.823	0.823	0.030 0.389	0.389	0.011 0.236	0.236


Supplementary Figure 1: Adjusted Regression plots. Adjusted mean retinal pigment score by covariates of interest. Adjusted means (solid black dots), 95% confidence intervals (vertical solid lines), and regression line for continuous variables (dotted line) are from a linear regression model adjusting for age, sex, and UK biobank centre. *M, myopia; E, emmetropia; H, hyperopia.




Supplementary Figure 2. Traits that are significantly enriched for prioritised genes from the discovery genome-wide association study, as evidenced by previously reported gene-trait associations in the GWAS Catalog.



Supplementary Figure 3. Gene Ontology biological pathways from MsigDB significantly enriched for prioritised genes from the discovery genome-wide association study.



Supplementary Figure 4: PheWAS Volcano Plot



Supplementary Figure 4. Volcano plot summarising phenotype-wide association study results, showing potential associations between retinal pigment score (RPS) with 308 health conditions. The dashed blue line indicates $p=0.05$, while the dashed red line indicates the Bonferroni-adjusted significance threshold $p=0.05/308$ tests. Log odds are per standard deviation increase in RPS.

References

- [1] Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 10 2018;562:203–9.
- [2] Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* 2017;8:1826.
- [3] Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* 07 2021;53:1097–103.
- [4] Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 03 2012;44. <https://doi.org/10.1038/ng.2213>.
- [5] Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 03 2015;47:291–5.
- [6] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2022.
- [7] Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for genome-wide association studies in the R environment. *Bioinformatics* 2014;30:2375–6.
- [8] Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human genome. *eLife* 2018;7. <https://doi.org/10.7554/eLife.34408>.
- [9] Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol* 2017;46:1734–9.
- [10] Warwick A. ukbwrranglr: Functions to load and wrangle UK Biobank data. 2022.
- [11] Warwick A. codemapper: Functions for mapping between clinical coding systems. 2022.
- [12] Landau WM. The targets R package: a dynamic Make-like function-oriented pipeline toolkit for reproducibility and high-performance computing. *Journal of Open Source Software* 2021;6:2959.
- [13] Landau WM. tarchetypes: Archetypes for Targets. 2021.
- [14] Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the tidyverse. *Journal of Open Source Software* 2019;4:1686.
- [15] Blischak JD, Carbonetto P, Stephens M. Creating and sharing reproducible research code the workflowr way [version 1; peer review: 3 approved]. *F1000Res* 2019;8. <https://doi.org/10.12688/f1000research.20843.1>.
- [16] Gohel D. flextable: Functions for Tabular Reporting. 2022.
- [17] Sjoberg D, Whiting K, Curry M, Lavery J, Larmarange J. Reproducible Summary Tables with the gtsummary Package. *R J* 2021;13:570.
- [18] Xie Y. knitr: A General-Purpose Package for Dynamic Report Generation in R. 2022.
- [19] Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* 2023;613:508–18.
- [20] 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. *Nature* 2015;526:68–74.
- [21] Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* 2011;40:755–64.
- [22] Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I² statistic. *Int J Epidemiol* 2016;45:1961–74.
- [23] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–25.